AMRN Mar 2023 1.000 call
| Previous Close | 0.9400 |
| Open | 0.9300 |
| Bid | 0.8000 |
| Ask | 0.9000 |
| Strike | 1.00 |
| Expire Date | 2023-03-17 |
| Day's Range | 0.9300 - 0.9400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.22k |
- GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides. Cardiovascular disease is a significant health issue for people li
- GlobeNewswire
Amarin to Present at SVB Securities Global Biopharma Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference (February 13-16th, 2023; Virtual) Date/Time: February 14, 2023 10:40 a.m. ET Webcast: https://wsw.com/webcast/svb8/register.aspx?conf=svb8&page=amrn&url=https://wsw.com/webcast/svb8/am
- Zacks
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
